Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Reckitt is a global leader in consumer health and hygiene, and is the parent company of the widely recognized analgesic brand Nurofen. Nurofen, which utilizes ibuprofen as its active pharmaceutical ingredient, is one of the world's most popular over-the-counter pain relief medications. Originally developed by Boots and launched in 1983, the brand was acquired by Reckitt Benckiser in 2006 as part of a strategic expansion into the healthcare sector. Reckitt markets Nurofen in a variety of specialized formats, including liquid capsules, tablets, and pediatric suspensions, to address diverse needs such as tension headaches, muscular pain, and fever. The company continues to invest in the brand through innovations in drug delivery and fast-acting formulations. Beyond Nurofen, Reckitt's extensive health portfolio includes other major brands like Mucinex, Gaviscon, and Strepsils.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nurofen.